News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


GSK & WHO unite to fight malaria

GlaxoSmithKline , WHO-TDR and the Medicines For Malaria Venture collaborate to fight malaria

Auckland, April 29, 2004 - GlaxoSmithKline (GSK), the World Health Organisation's Special Programme for Research and Training in Tropical Diseases (WHO-TDR) and the Medicines for Malaria Venture (MMV) today announced the signing of a collaborative agreement, to develop a new-fixed dose artemisinin combination therapy drug (ACT), combining chlorproguanil, dapsone and artesunate (CDA) for the treatment of malaria.

In Africa, the malaria crisis is escalating mainly due to multi-drug resistance. The most frequently used treatments for malaria, such as chloroquine and sulfadoxine/ pyrimethamine (SP), are becoming less and less effective. To tackle drug resistant malaria, new treatments are urgently needed to provide effective therapy to the millions in need. The development of CDA responds to the World Health Organisation's 'Roll Back Malaria' recommendations for the National Malaria Control Programmes (NMCP) to use artemisinin based combination therapy as the preferred treatment of uncomplicated falciparum malaria.

"Partnership is essential to combine resources and expertise; and accelerate the process of providing safe, effective and affordable drugs. It is the best way to help ensure that a drug such as CDA gets to the people in need as quickly as possible", explained Chris Hentschel, CEO, MMV.

"WHO-TDR has already collaborated with GSK and other partners to successfully develop an antimalarial and we believe that developing a drug combining chlorproguanil, dapsone, and artesunate will enhance clinical efficacy in malaria treatment and also delay the development of resistance by the malaria parasites." said Robert Ridley, Acting Director, WHO-TDR.

"GSK is committed to participating in public-private partnerships such as this one for CDA, and to bringing urgently needed medicines to people in the developing world faster," said Dr Ian Griffiths, Medical Director, GlaxoSmithKline New Zealand.

This new CDA development project is based on the development of dapsone and chlorproguanil supported by an initial grant from the UK Department of International Development (DFID). The development team is chaired by Professor Peter Winstanley of the University of Liverpool, one of the academic partners involved in the development of the drug, along with the Liverpool School of Tropical Medicine and the London School of Hygiene & Tropical Medicine.

The agreement states that if the development of CDA is successful as a result of this initiative, it will be made available at preferential prices to the public sector in malaria endemic countries, so as to maximize its availability to those in need. If targets are met the drug should be ready for regulatory submission in 2006.

"This new treatment could be an important development in the fight against malaria", said Dr F Nafo-Traoré, Director of the Roll Back Malaria department, WHO. "We hope that it will prove useful in regions of Africa where resistance makes older antimalarials ineffective."

The World Health Organisation estimates that there are 300 - 500 million malaria cases annually, directly causing 1 million deaths and directly contributing to a further 1.7 million deathsi. It is the leading cause of death in young children in Africa. Hundreds of millions of African children and adults are chronically infected with malaria. Between 30 and 50% of inpatient admissions and 50% of outpatient visits are attributed to malaria each yearii. Beyond the human toll, malaria has significant economic impacts in the endemic countries - costing Africa $12 billion in lost GDP every year and consuming 40 percent of all public health spending.

Notes to Editors:

About MMV

Medicine for Malaria Venture was officially launched on 3 November 1999 as a non-profit foundation dedicated to reducing the burden of malaria in disease endemic countries by discovering, developing and delivering new affordable antimalarials through effective public-private partnership. After four years of operation, MMV is managing the largest portfolio of malaria research in history with 21 Projects in different stages of drug research and development. For further information please consult

About GSK

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline on the World Wide Web at ,nz


The Special Programme for Research and Training in Tropical Diseases (TDR) is a special programme co-sponsored by UNDP, WHO, UNICEF and the World Bank. It helps to coordinate, support and influence global efforts to combat a portfolio of major diseases of the poor and disadvantaged. TDR acts as a 'global facilitator' of research and training, providing guidance and grants for research priorities and opportunities in its targeted 10 neglected diseases.

i World Health Organisation, RBM Infosheet 1 of 11, March 2002

ii World Health Organisation, RBM Infosheet 1 of 11, March 2002

© Scoop Media

Culture Headlines | Health Headlines | Education Headlines


Electronica: Restoring The World’s First Recorded Computer Music

University of Canterbury Distinguished Professor Jack Copeland and UC alumni and composer Jason Long have restored the earliest known recording of computer-generated music, created more than 65 years ago using programming techniques devised by Alan Turing. More>>


Scoop Review Of Books: Almost Getting Away With Murder

The Black Widow by Lee-Anne Cartier: Lee-Anne Cartier is the sister of the Christchurch man found to have been murdered by his wife, Helen Milner, after an initial assumption by police that his death, in 2009, was suicide. More>>

Howard Davis: Triple Echo - The Malevich/Reinhardt/Hotere Nexus

Howard Davis: The current juxtaposition of works by Ralph Hotere and Ad Reinhardt at Te Papa perfectly exemplifies Jean Michel Massing's preoccupation with the transmigration of imagery in a remarkable triple echo effect... More>>

Scoop Review Of Books: Nō Tāu Manawa

Vaughan Rapatahana responds to Fale Aitu | Spirit House by Tusiata Avi: "fa’afetai Tusiata, fa’afetai, / you’ve swerved & served us a masterclass corpus / through graft / of tears & fears..." More>>

9 Golds - 21 Medals: NZ Team Celebrates As Rio 2016 Paralympic Games Close

The entire New Zealand Paralympic Team, led by kiwi sprinter and double gold medallist Liam Malone as flag bearer, are on the bus to the Maracanã Stadium in Rio de Janeiro for the Closing Ceremony of the Rio 2016 Paralympic Games. There, they will celebrate the fantastic successes of the past 10 days. More>>


New Zealand Improv Festival: The Festival Of Moments To Return To The Capital

The eighth incarnation of the New Zealand Improv Festival comes to BATS Theatre this 4-8 October , with a stellar line-up of spontaneous theatre and instant comedy performed and directed by top improvisors from around New Zealand and the world. More>>


Get More From Scoop



Search Scoop  
Powered by Vodafone
NZ independent news